Conversely, inhibition of SUMOylation provided promising results in pre-clinical cancer models, and depletion of Ubc9 or SUMO-activating enzyme subunit 2 (SAE2) inactivated c-Myc oncogenic mutations and enhanced immune and chemotherapy sensitivity in small cell lung cancer (26–58). This evidence concerns the gene MYC and small cell lung carcinoma.